Vor Biopharma Inc (VOR)

$0.92

+0.01

(+0.69%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $0.91
    $0.97
    $0.92
    downward going graph

    1.3%

    Downside

    Day's Volatility :6.07%

    Upside

    4.83%

    downward going graph
  • $0.90
    $3.48
    $0.92
    downward going graph

    2.17%

    Downside

    52 Weeks Volatility :74.14%

    Upside

    73.56%

    downward going graph

Returns

PeriodVor Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
-49.27%
6.4%
0.0%
6 Months
-61.53%
6.0%
0.0%
1 Year
-72.02%
9.6%
0.0%
3 Years
-93.74%
14.8%
-19.4%

Highlights

Market Capitalization
62.6M
Book Value
$1.8
Earnings Per Share (EPS)
-1.77
Wall Street Target Price
14.06
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-35.97%
Return On Equity TTM
-68.07%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-124.3M
Diluted Eps TTM
-1.77
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.61
EPS Estimate Next Year
-1.37
EPS Estimate Current Quarter
-0.38
EPS Estimate Next Quarter
-0.4

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Vor Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1428.26%

Current $0.92
Target $14.06

Technicals Summary

Sell

Neutral

Buy

Vor Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vor Biopharma Inc
Vor Biopharma Inc
-23.06%
-61.53%
-72.02%
-93.74%
-95.51%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vor Biopharma Inc
Vor Biopharma Inc
NA
NA
NA
-1.61
-0.68
-0.36
NA
1.8
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vor Biopharma Inc
Vor Biopharma Inc
Buy
$62.6M
-95.51%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Vor Biopharma Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 131.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 294.3%

Institutional Holdings

  • RA Capital Management, LLC

    33.33%
  • FMR Inc

    11.15%
  • Paradigm Biocapital Advisors LP

    9.46%
  • 5AM Venture Management, LLC

    9.32%
  • LAURION CAPITAL MANAGEMENT LP

    4.66%
  • BlackRock Inc

    3.29%

Company Information

vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar

Organization
Vor Biopharma Inc
Employees
168
CEO
Dr. Robert Ang M.B.A., M.D., MBBS
Industry
Services

FAQs